NTRB
Nutriband Inc.
Set alert
6.30 USD -0.34 -5.12%
6.20 Day range 6.42
2.81 52-week range 8.99
- YTD
- +38.77%
- 1 year
- -8.83%
- Open
- 6.30
- Prev close
- 6.64
- Mkt cap
- 76.58M
- Vol
- 22.23K
- Avg vol
- 68.47K
- EPS
- -0.53
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.20
- High
- 6.42
- Forward P/E
- -17.30
- Beta
- 0.42
- Short ratio
- 1.53
- Inst. own
- 2.38%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 5.30
- 200-d avg
- 5.09
- 1y target
- 0.00
Key statistics
- Market cap
- 44.20M
- Enterprise value
- 44.16M
- Trailing P/E
- 0.00
- Forward P/E
- -17.30
- PEG ratio
- 0.00
- Price / sales
- 21.92
- Price / book
- 5.47
- EPS (TTM)
- -0.71
- Beta
- 0.42
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 2.02M
- Revenue growth
- -14.30%
- Free cash flow
- -1.55M
- Total cash
- 8.35M
- Total debt
- 527.92K
- Return on equity
- -60.41%
- Shares outstanding
- 11.11M
- Short % of float
- 1.00%
- 50-day average
- 5.30
- 200-day average
- 5.09
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
NTRB Revenue — quarterly 437.51K
NTRB Net income — quarterly -880.56K
NTRB EPS — quarterly -0.07
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 3, 2024 | Oct 1, 2024 | 0.00 | -0.12 | — | — |
| Sep 3, 2024 | Jul 1, 2024 | 0.00 | -0.12 | — | — |
| May 31, 2024 | Apr 1, 2024 | 0.00 | -0.21 | — | — |
| Apr 30, 2024 | Jan 1, 2024 | 0.00 | -0.16 | — | — |
| Dec 12, 2023 | Oct 1, 2023 | 0.00 | -0.22 | — | — |
| Sep 11, 2023 | Jul 1, 2023 | 0.00 | -0.11 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 26, 2022 | Small Cap Consumer Research | main | — | Buy |
About Nutriband Inc.
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- nutriband.com
News
- Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $1,753,274
- Nutriband Files U.S. Patent Application To Increase Protection For Its AVERSA Abuse Deterrent Transdermal Technology
- Nutriband Files New Patent Application to Strengthen Intellectual Property Protection of Its Transdermal Abuse Deterrent Technology
- Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders
- Head to Head Contrast: ARS Pharmaceuticals (NASDAQ:SPRY) and Nutriband (NASDAQ:NTRB)
- Nutriband CEO Gareth Sheridan Featured in New Nick Shirley Documentary Confronting America's Opioid Crisis
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Why Webuy Global Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Friday's Intraday Session
- Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing
Your note
Sign in to keep a note on NTRB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| MELNIK SERGUEI | President | Stock Gift | Mar 5, 2023 | 827,999 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 1.86% | 118,063 | 469.89K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.91% | 58,063 | 231.09K | Sep 29, 2024 |
| UBS Group AG | 0.32% | 20,352 | 81.00K | Sep 29, 2024 |
| Avantax Advisory Services, Inc. | 0.29% | 18,678 | 74.34K | Sep 29, 2024 |
| State Street Corporation | 0.27% | 17,266 | 68.72K | Sep 29, 2024 |
| Farther Finance Advisors, Llc | 0.25% | 16,014 | 63.73K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.13% | 71,575 | 284.87K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.69% | 43,788 | 174.28K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.46% | 29,333 | 116.75K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.16% | 9,882 | 39.33K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.11% | 7,260 | 28.89K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.11% | 6,718 | 26.74K | Oct 30, 2024 |